Drug Profile

SCI 160

Alternative Names: SCI-160; THX-160

Latest Information Update: 06 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hebrew University of Jerusalem
Developer SciSparc
Class Analgesics; Cannabinoids
Mechanism of Action Cannabinoid receptor CB2 agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Neuropathic pain; Pain; Postoperative pain

Most Recent Events

30 Jan 2025 Polurizon files for patents protection with Israel Patent Office for Trap and Target T&T™ technology
19 Dec 2024 Polurizon has patents pending for Trap and Target T&T™ technology in USA
27 Aug 2024 Preclinical development is ongoing for Pain in Israel

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com